The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Cognitive decline is faster in Lewy body variant than in Alzheimer's disease
Abstract
OBJECTIVES: To quantify the rate of cognitive decline on the Mini-Mental State Examination (MMSE) in autopsy-diagnosed Lewy body variant (LBV) of Alzheimer's disease (AD) cases. We hypothesized that LBV patients would have a faster cognitive decline and shorter survival compared with patients with pure AD. BACKGROUND: Prior reports have shown extrapyramidal signs to be associated with a poorer prognosis in AD. It has been suggested that LBV is often characterized by a rapidly progressive course. Few data are available regarding the rate of cognitive decline in autopsy-confirmed LBV dementia cases. METHODS: We searched the databases of the University of California-San Diego Alzheimer's Disease Research Center and the Consortium to Establish a Registry in Alzheimer's Disease (CERAD) for dementia cases with 1) an autopsy diagnosis of definite or probable AD (CERAD criteria) with concomitant Lewy bodies and 2) longitudinal MMSE assessments. This resulted in a series of 40 LBV cases and 148 AD cases without Lewy bodies, with comparable baseline MMSE scores, age, and education. The rate of cognitive decline was calculated as the baseline MMSE -- final MMSE. Methods were devised to reduce floor effects on the MMSE. RESULTS: The average rate of cognitive decline was -5.8 +/- 4.5 points/y in LBV and -4.1 +/- 3.0 points/y in AD (t-test, p < 0.01). The LBV group declined a similar amount on the MMSE (means, -10.0 versus -9.6 points) over a significantly shorter time interval (1.9 versus 2.7 years; p = 0.005) than did AD patients. At baseline, the mean MMSE scores were nearly identical (18.2 in LBV; 17.8 in AD), but on follow-up examinations approximately 1, 2, and 3 years later, there were intergroup mean differences of 1.8 points (two-tailed p = 0.19), 4.2 points (p = 0.04), and 5.6 points (p = 0.03), respectively. The LBV cases had shorter survival time from the onset of cognitive symptoms (7.7 +/- 3.0 years versus 9.3 +/- 3.5 years; p = 0.007) and a shorter mean survival after entry/baseline, which was of marginal significance (3.6 versus 4.1 years; p = 0.11). CONCLUSIONS: This study demonstrates that LBV is characterized by a faster cognitive decline and accelerated mortality compared with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Operational criteria for senile dementia of Lewy body type (SDLT)
McKeith, I. G., Perry, R. H., Fairbairn, A. F., Jabeen, S., & Perry, E. K. (1992) · Psychological Medicine · doi:10.1017/s0033291700038484 · Cited by 431
Neurosurgical horizons in Parkinson's disease
Goetz, C. G., De Long, M. R., Penn, R. D., & Bakay, R. A. E. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.1 · Cited by 405
Mayeux, R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530290076015 · Cited by 383
Membrane Dynamics at the Endoplasmic Reticulum–Golgi Interface
Bannykh, S. I., & Balch, W. E. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.1.1 · Cited by 241
On the production of neurologists in the United States: An update
Kurtzke, J. F., Murphy, F. M., & Smith, M. A. (1991) · Neurology · doi:10.1212/wnl.41.1.1 · Cited by 220
Grant, I., Brown, G. W., Harris, T., McDonald, W. I., Patterson, T., & Trimble, M. R. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.1.8 · Cited by 188
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies.
Schmidt, M. L., Murray, J., Lee, V. M. Y., Hill, W. D., Wertkin, A. M., & Trojanowski, J. Q. (1991) · PubMed Central · Cited by 161
Cited by
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Hamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754
Neuroinflammation as a common feature of neurodegenerative disorders
Guzman-Martinez, L., Maccioni, R. B., Andrade, V., Navarrete, L. P., Pastor, M. G., & Ramos-Escobar, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01008 · Cited by 702
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643
Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576
Minoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560
“There are suggestions of differential responses to cholinesterase inhibitor treatment(7) and prognosis between the two diseases.(8) Adverse responses to certain drug treatments, such as severe and potentially fatal neuroleptic sensitivity, are reported to occur more often in DLB.”
BackgroundBurn, D. J. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.081711 · Cited by 436
Bonanni, L., Thomas, A., Tiraboschi, P., Perfetti, B., Varanese, S., & Onofrj, M. (2008) · Brain · doi:10.1093/brain/awm322 · Cited by 379
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias
Bakulski, K. M., Seo, Y. A., Hickman, R. C., Brandt, D., Vadari, H. S., Hu, H., & Park, S. K. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200282 · Cited by 345
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies
Merdes, A. R., Hansen, L. A., Jeste, D. V., Galasko, D., Hofstetter, C. R., Ho, G. J., Thal, L. J., & Corey-Bloom, J. (2003) · Neurology · doi:10.1212/01.wnl.0000065889.42856.f2 · Cited by 322
Self-citationCognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both
Kraybill, M. L., Larson, E. B., Tsuang, D. W., Teri, L., McCormick, W. C., Bowen, J. D., Kukull, W. A., Leverenz, J. B., & Cherrier, M. M. (2005) · Neurology · doi:10.1212/01.wnl.0000165987.89198.65 · Cited by 287
Low sensitivity in clinical diagnoses of dementia with Lewy bodies
Nelson, P. T., Jicha, G. A., Kryscio, R. J., Abner, E. L., Schmitt, F. A., Cooper, G., Xu, L. O., Smith, C. D., & Markesbery, W. R. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5324-y · Cited by 274
Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273
What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?
Tiraboschi, P., Salmon, D. P., Hansen, L. A., Hofstetter, R. C., Thal, L. J., & Corey-Bloom, J. (2006) · Brain · doi:10.1093/brain/awh725 · Cited by 272
Self-citationTDP‐43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing
McAleese, K. E., Walker, L., Erskine, D., Thomas, A. J., McKeith, I. G., & Attems, J. (2017) · Brain Pathology · doi:10.1111/bpa.12424 · Cited by 262
Motor signs during the course of Alzheimer disease
Scarmeas, N., Hadjigeorgiou, G. M., Papadimitriou, A., Dubois, B., Sarazin, M., Brandt, J., Albert, M., Marder, K., Bell, K., Honig, L. S., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000138440.39918.0c · Cited by 256
Brodaty, H., Seeher, K., & Gibson, L. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002924 · Cited by 248
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
Williams, M. M., Xiong, C., Morris, J. C., & Galvin, J. E. (2006) · Neurology · doi:10.1212/01.wnl.0000247041.63081.98 · Cited by 239
Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366336 · Cited by 198
Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample
Brenowitz, W. D., Hubbard, R. A., Keene, C. D., Hawes, S. E., Longstreth, W. T., Woltjer, R. L., & Kukull, W. A. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.015 · Cited by 188
“LBD in ADNP may be the result of a distinct pathogenesis and clinical course compared with ADNP only [47,49].”
BackgroundResultAPOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid
Zhao, N., Attrebi, O. N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y. A., Meneses, A. D., Li, F., Shue, F., Zheng, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1809 · Cited by 156
Geschwind, M. D., Haman, A., & Miller, B. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.04.001 · Cited by 143
Trajectories of cognitive decline in different types of dementia
Smits, L. L., van Harten, A. C., Pijnenburg, Y. A. L., Koedam, E. L. G. E., Bouwman, F. H., Sistermans, N., Reuling, I. E. W., Prins, N. D., Lemstra, A. W., Scheltens, P., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291714002153 · Cited by 134
“It is often thought that DLB is one of the fastest declining types of dementia but our findings do not support this idea and earlier results seem conflicting (Olichney et al. 1998; Walker et al. 2012).”
ResultAssociation between male gender and cortical Lewy body pathology in large autopsy series
Nelson, P. T., Schmitt, F. A., Jicha, G. A., Kryscio, R. J., Abner, E. L., Smith, C. D., Van Eldik, L. J., & Markesbery, W. R. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5630-4 · Cited by 131
“This approach was chosen partly because DLB and AD ? DLB tend to have distinct clinical manifestations [10, 19, 24].”
MethodRETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128
“The presence of these additional lesions does not appear to be innocuous, as subjects presenting with the LB variant of AD generally display a more rapid rate of cognitive decline than subjects with AD alone (Olichney et al., 1998).”
BackgroundRetractedRelative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies
Nelson, P. T., Kryscio, R. J., Jicha, G. A., Abner, E. L., Schmitt, F. A., Xu, L. O., Cooper, G., Smith, C. D., & Markesbery, W. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bacf9e · Cited by 99
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
“About 10–40% of AD patients have concomitant Lewy bodies [106–108], which likely affects the clinical course of AD, since AD patients with Lewy bodies have faster cognitive decline than those without Lewy bodies [109].”
BackgroundJin, Y., Li, F., Sonoustoun, B., Kondru, N. C., Martens, Y. A., Qiao, W., Heckman, M. G., Ikezu, T. C., Li, Z., Burgess, J. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02421-8 · Cited by 69
Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons
Khan, S. S., LaCroix, M., Boyle, G., Sherman, M. A., Brown, J. L., Amar, F., Aldaco, J., Lee, M. K., Bloom, G. S., & Lesné, S. E. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1886-z · Cited by 41
Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9190-2 · Cited by 34
Wang, H., Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171013 · Cited by 33
Self-citation18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies
Graff-Radford, J., Lesnick, T. G., Savica, R., Chen, Q., Ferman, T. J., Przybelski, S. A., Jones, D. T., Senjem, M. L., Gunter, J. L., Kremers, W. K., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa040 · Cited by 28
Metadata
- Authors
- Olichney, J. M., Galasko, D., Salmon, D. P., Hofstetter, C. R., Hansen, L. A., Katzman, R., & Thal, L. J.
- Venue
- Neurology
- Published
- 1998-08
- Volume
- 51
- Issue
- 2
- Pages
- 351-357
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1982334187
- Cited by
- 305
- References
- 24
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.